SEARCH

SEARCH BY CITATION

References

  • Abshagen, U., Sporl-Radun, S. & Marinow, J. (1980) Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. European Journal of Clinical Pharmacology, 17, 305308.
  • Bunce, C.M., Mountford, J.C., French, P.J., Mole, D.J., Durham, J., Michell, R.H. & Brown, G. (1996) Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochimica et Biophysica Acta, 1311, 189198.
  • Burnett, A.K. & Mohite, U. (2006) Treatment of older patients with acute myeloid leukemia–new agents. Seminars in Hematology, 43, 96106.
  • Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M.F., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, R.K. & Wheatley, K. (2009) The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology, 145, 318332.
  • Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., De Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 36713674.
  • Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. Journal of Clinical Oncology, 21, 46424649.
  • Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., De Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419425.
  • Derolf, A.R., Kristinsson, S.Y., Andersson, T.M., Landgren, O., Dickman, P.W. & Bjorkholm, M. (2009) Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood, 113, 36663672.
  • Deschler, B., De Witte, T., Mertelsmann, R. & Lubbert, M. (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica, 91, 15131522.
  • Dollery, C. (1999) Therapeutic Drugs. Churchill Livingstone, Edinburgh (Scotland).
  • Estey, E. (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. Journal of Clinical Oncology, 25, 19081915.
  • Fenton, S.L., Drayson, M.T., Hewison, M., Vickers, E., Brown, G. & Bunce, C.M. (1999) Clofibric acid: a potential therapeutic agent in AML and MDS. British Journal of Haematology, 105, 448451.
  • Gehan, E.A. (1961) The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases, 13, 346353.
  • Gerster, H. (1997) Vitamin A–functions, dietary requirements and safety in humans. International Journal for Vitamin and Nutrition Research, 67, 7190.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 38353849.
  • Institute of Medicine, Food and Nutrition Board. (1999) Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. National Academy Press, Washington, DC.
  • Khanim, F.L., Hayden, R.E., Birtwistle, J., Lodi, A., Tiziani, S., Davies, N.J., Ride, J.P., Viant, M.R., Gunther, U.L., Mountford, J.C., Schrewe, H., Green, R.M., Murray, J.A., Drayson, M.T. & Bunce, C.M. (2009) Combined bezafibrate and medroxyprogesterone acetate: Potential novel therapy for acute myeloid leukaemia. PLoS ONE, 4, e8147.
  • Kohrt, H.E. & Coutre, S.E. (2008) Optimizing therapy for acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 6, 10031016.
  • Kuendgen, A. & Germing, U. (2009) Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treatment Reviews, 35, 97120.
  • Ohtsu, T., Fujii, H., Wakita, H., Igarashi, T., Itoh, K., Imoto, S., Kohagura, M. & Sasaki, Y. (1998) Pharmacokinetic study of low- versus high-dose medroxyprogesterone acetate (MPA) in women. Cancer Chemotherapy and Pharmacology, 42, 18.
  • Scatena, R., Nocca, G., Sole, P.D., Rumi, C., Puggioni, P., Remiddi, F., Bottoni, P., Ficarra, S. & Giardina, B. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death and Differentiation, 6, 781787.
  • Tallman, M.S., Gilliland, D.G. & Rowe, J.M. (2005) Drug therapy for acute myeloid leukemia. Blood, 106, 11541163.
  • Thigpen, J.T., Brady, M.F., Alvarez, R.D., Adelson, M.D., Homesley, H.D., Manetta, A., Soper, J.T. & Given, F.T. (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. Journal of Clinical Oncology, 17, 17361744.
  • Trof, R.J., Beishuizen, A., Wondergem, M.J. & Strack van Schijndel, R.J. (2007) Spontaneous remission of acute myeloid leukaemia after recovery from sepsis. Netherlands Journal of Medicine, 65, 259262.
  • Wheatley, K., Goldstone, A.H., Littlewood, T., Hunter, A. & Burnett, A.K. (2009a) Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. British Journal of Haematology, 146, 5463.
  • Wheatley, K., Brookes, C.L., Howman, A.J., Goldstone, A.H., Milligan, D.W., Prentice, A.G., Moorman, A.V. & Burnett, A.K. (2009b) Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology, 145, 598605.